Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 36 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Tiragolumab with atezolizumab for treating stage III non-small cell lung cancer after platinum-based chemoradiotherapy	Atezolizumab (Tecentriq; MPDL3280A) , Tiragolumab (RG-6058; MTIG7192A)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2023	View \| Download
Tiragolumab with atezolizumab for previously untreated non-small cell lung cancer	Atezolizumab (Tecentriq; MPDL3280A) , Tiragolumab (RG-6058; MTIG7192A)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2022	View \| Download
Tiragolumab with atezolizumab for oesophageal squamous cell cancer	Atezolizumab (Tecentriq; MPDL3280A) , Tiragolumab (RG-6058; MTIG7192A)	Oesophageal squamous cell carcinoma	Head and Neck Cancer	2023	View \| Download
Tiragolumab with atezolizumab and pemetrexed and carboplatin or cisplatin for previously untreated advanced non-small-cell lung cancer	Atezolizumab (Tecentriq; MPDL3280A) , Tiragolumab (RG-6058; MTIG7192A)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2023	View \| Download
Subcutaneous atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer	Atezolizumab (Tecentriq; MPDL3280A)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2022	View \| Download
Neoadjuvant atezolizumab with chemotherapy followed by adjuvant atezolizumab for treating triple-negative breast cancer	Atezolizumab (Tecentriq; MPDL3280A) , Chemotherapy	Breast cancer	Breast Cancer	2022	View \| Download
Lurbinectedin with atezolizumab maintenance therapy for extensive-stage small-cell lung cancer	Atezolizumab (Tecentriq; MPDL3280A) , Lurbinectedin (PM01183; Zepzelca)	Small-cell lung cancer (SCLC)	Lung and Respiratory Cancer	2023	View \| Download
Cabozantinib with atezolizumab for treating metastatic castration-resistant prostate cancer after one novel hormonal therapy	Atezolizumab (Tecentriq; MPDL3280A) , Cabozantinib (XL-184; Cabometyx; Cometriq; XL 184)	Prostate cancer	Haematological Cancer and Lymphomas , Oncology	2023	View \| Download
Cabozantinib in combination with atezolizumab for advanced hepatocellular carcinoma –first line	Atezolizumab (Tecentriq; MPDL3280A) , Cabozantinib (XL-184; Cabometyx; Cometriq; XL 184)	Hepatocellular carcinoma (HCC)	Gastrointestinal Cancer	2021	View \| Download
Atezolizumab with platinum-based chemotherapy and bevacizumab for epithelial ovarian cancer or fallopian tube cancer or primary peritoneal cancer	Atezolizumab (Tecentriq; MPDL3280A) , Bevacizumab (Avastin; R 435; RG 405; RG 435) , Chemotherapy	Epithelial ovarian cancer , Fallopian tube cancer , primary peritoneal cancer	Female Reproductive Cancer	2022	View \| Download